Literature DB >> 25127690

The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML).

Kathleen Elliot1, Janet A Tooze2, Rachel Geller3, Bayard L Powell4, Timothy S Pardee5, Ellen Ritchie6, LeAnne Kennedy7, Kathryn E Callahan8, Heidi D Klepin9.   

Abstract

We retrospectively evaluated the prognostic significance of polypharmacy and inappropriate medication use among 150 patients >60 years of age receiving induction chemotherapy for acute myelogenous leukemia (AML). After adjustment for age and comorbidity, increased number of medications at diagnosis (≥ 4 versus ≤ 1) was associated with increased 30-day mortality (OR=9.98, 95% CI=1.18-84.13), lower odds of complete remission status (OR=0.20, 95% CI=0.06-0.65), and higher overall mortality (HR=2.13, 95% CI=1.15-3.92). Inappropriate medication use (classified according to Beers criteria) was not significantly associated with clinical outcomes. Polypharmacy warrants further study as a modifiable marker of vulnerability among older adults with AML.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Elderly; Leukemia; Medications; Mortality; Older; Polypharmacy

Mesh：

Substances：

Year:  2014        PMID： 25127690      PMCID： PMC4182134          DOI： 10.1016/j.leukres.2014.06.018

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  46 in total

1.  Survival for older patients with acute myeloid leukemia: a population-based study.

Authors:  Betul Oran; Daniel J Weisdorf
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy.

Authors:  Marije E Hamaker; M Mitrovic; R Stauder
Journal:  Ann Hematol       Date:  2014-02-02       Impact factor: 3.673

3.  Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.

Authors:  Utz Krug; Christoph Röllig; Anja Koschmieder; Achim Heinecke; Maria Cristina Sauerland; Markus Schaich; Christian Thiede; Michael Kramer; Jan Braess; Karsten Spiekermann; Torsten Haferlach; Claudia Haferlach; Steffen Koschmieder; Christian Rohde; Hubert Serve; Bernhard Wörmann; Wolfgang Hiddemann; Gerhard Ehninger; Wolfgang E Berdel; Thomas Büchner; Carsten Müller-Tidow
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

4.  Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes.

Authors:  Alexander E Sherman; Gabriela Motyckova; K Rebecca Fega; Daniel J Deangelo; Gregory A Abel; David Steensma; Martha Wadleigh; Richard M Stone; Jane A Driver
Journal:  Leuk Res       Date:  2013-06-06       Impact factor: 3.156

5.  Age and acute myeloid leukemia.

Authors:  Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

6.  Beers criteria as a proxy for inappropriate prescribing of other medications among older adults.

Authors:  Brian C Lund; Michael A Steinman; Elizabeth A Chrischilles; Peter J Kaboli
Journal:  Ann Pharmacother       Date:  2011-10-04       Impact factor: 3.154

7.  Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

Authors:  Hagop Kantarjian; Farhad Ravandi; Susan O'Brien; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; William Wierda; Tapan Kadia; Sherry Pierce; Jianqin Shan; Michael Keating; Emil J Freireich
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

8.  Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology-acute care for elders unit.

Authors:  Kellie L Flood; Maria B Carroll; Cyndi V Le; Cynthia J Brown
Journal:  Am J Geriatr Pharmacother       Date:  2009-06

9.  Validation of a combined comorbidity index.

Authors:  M Charlson; T P Szatrowski; J Peterson; J Gold
Journal:  J Clin Epidemiol       Date:  1994-11       Impact factor: 6.437

10.  Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study.

Authors:  Yu Ko; Sze-Ling Daphne Tan; Alexandre Chan; Yuet-Peng Wong; Wei-Peng Yong; Raymond Chee-Hui Ng; Siew-Woon Lim; Agus Salim
Journal:  Clin Ther       Date:  2012-07-15       Impact factor: 3.393
View more
  18 in total

Review 1.  Elderly acute myeloid leukemia: assessing risk.

Authors:  Heidi D Klepin
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

Review 2.  Polypharmacy and potentially inappropriate medication use in geriatric oncology.

Authors:  Manvi Sharma; Kah Poh Loh; Ginah Nightingale; Supriya G Mohile; Holly M Holmes
Journal:  J Geriatr Oncol       Date:  2016-08-03       Impact factor: 3.599

Review 3.  Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia.

Authors:  Nicholas J Short; Hagop Kantarjian; Elias Jabbour; Farhad Ravandi
Journal:  Curr Hematol Malig Rep       Date:  2018-04       Impact factor: 3.952

Review 4.  Using Information Technology in the Assessment and Monitoring of Geriatric Oncology Patients.

Authors:  Kah Poh Loh; Colin McHugh; Supriya G Mohile; Karen Mustian; Marie Flannery; Heidi Klepin; Rebecca Schnall; Eva Culakova; Erika Ramsdale
Journal:  Curr Oncol Rep       Date:  2018-03-06       Impact factor: 5.075

Review 5.  Polypharmacy in the Geriatric Oncology Population.

Authors:  Lauren R Hersh; Kathryn Beldowski; Emily R Hajjar
Journal:  Curr Oncol Rep       Date:  2017-09-23       Impact factor: 5.075

6.  Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care.

Authors:  Rebecca L Olin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

7.  Polypharmacy in Patients with Ovarian Cancer.

Authors:  Sean Oldak; Stephanie Ioannou; Priyanka Kamath; Marilyn Huang; Sophia George; Brian Slomovitz; Matthew Schlumbrecht
Journal:  Oncologist       Date:  2019-04-05

Review 8.  Definition of Unfit for Standard Acute Myeloid Leukemia Therapy.

Authors:  Heidi D Klepin
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

9.  Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance).

Authors:  Heidi D Klepin; Ellen Ritchie; Brittny Major-Elechi; Jennifer Le-Rademacher; Drew Seisler; Libby Storrick; Ben L Sanford; Guido Marcucci; Weiqiang Zhao; Susan A Geyer; Karla V Ballman; Bayard L Powell; Maria R Baer; Wendy Stock; Harvey Jay Cohen; Richard M Stone; Richard A Larson; Geoffrey L Uy
Journal:  J Geriatr Oncol       Date:  2019-10-24       Impact factor: 3.599

10.  Associations of Polypharmacy and Inappropriate Medications with Adverse Outcomes in Older Adults with Cancer: A Systematic Review and Meta-Analysis.

Authors:  Mostafa R Mohamed; Erika Ramsdale; Kah Poh Loh; Asad Arastu; Huiwen Xu; Spencer Obrecht; Daniel Castillo; Manvi Sharma; Holly M Holmes; Ginah Nightingale; Katherine M Juba; Supriya G Mohile
Journal:  Oncologist       Date:  2019-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.